Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

Wigginton to lead R&D at Bright Peak

Plus: a Mythic farewell for Nichols, Biswas joins CDR-Life as CMO and updates from Brii, Ansa, Kyverna, AskBio and more

August 23, 2022 10:00 PM UTC

Immunotherapy company Bright Peak Therapeutics Inc. named Jon Wigginton as president of R&D. Most recently, Wigginton was senior adviser and chairman of the scientific advisory board of Cullinan Oncology Inc. (NASDAQ:CGEM), having previously been that company’s CMO. Prior to that, he was CMO at MacroGenics Inc. (NASDAQ:MGNX).

Antibody company CDR-Life Inc. hired Swethajit Biswas as CMO. Biswas was a development leader at Adaptimmune Therapeutics plc and clinical director in oncology drug development at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). CDR is harnessing the high affinity of antibody fragments to develop a new class of bispecifics that can target intracellular cancer antigens...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article